JAK2 and RAS mutation status at different stages of the disease
| Gene . | Disease phase . | |||
|---|---|---|---|---|
| CP . | BP . | Remission (after induction) . | Remission (after consolidation) . | |
| JAK2 | V617F | WT | V617F | V617F |
| NRAS | NA | G12D | WT | WT |
| Gene . | Disease phase . | |||
|---|---|---|---|---|
| CP . | BP . | Remission (after induction) . | Remission (after consolidation) . | |
| JAK2 | V617F | WT | V617F | V617F |
| NRAS | NA | G12D | WT | WT |
Pyrosequencing-based assays developed by molecular laboratory at M. D. Anderson Cancer Center were used for mutation detection with sensitivity of 5%.
CP indicates chronic phase; BP, blast phase; NA, not available; and WT, wild-type.